

PHYTOINTELLIGENCE 2.0 MASTER RESEARCH PROTOCOL:

Precision Modulation of HLA-DRB1 (SE) and PTPN22 (R620W) in Rheumatoid Arthritis Pathogenesis

Marie-Soleil Seshat Landry
Chief Investigator, PhytoIntelligence Division

January 5, 2026

MANDATORY SOVEREIGN DISCLAIMER

NOTICE OF LIABILITY AND JURISDICTION: This document constitutes a theoretical research protocol intended solely for educational, informational, and experimental validation purposes within a private, non-commercial jurisdiction. It does not constitute medical advice, diagnosis, or treatment. The content herein is derived from the *PhytoIntelligence 2.0* framework and is protected under the rights of Sovereign Research. No content within this manuscript is to be construed as an offer to cure disease. The author, Marie-Soleil Seshat Landry, and associated entities assume no liability for the application of these bio-chemical formulations. Any utilization of this protocol is done at the sole risk and discretion of the user. This document is not compliant with FDA/EMA regulations for pharmaceutical marketing and remains a Sovereign expression of scientific inquiry.

1. COVER: PROTOCOL SPECIFICATIONS

Protocol ID: PHYTO-ARTH-2025-SE-R620W

Principal Investigator: Marie-Soleil Seshat Landry

Target Pathology: Seropositive Rheumatoid Arthritis (RA)

Genomic Targets:

- *HLA-DRB1* Shared Epitope (SE) alleles (*04:01, *04:04)
- *PTPN22* rs2476601 (R620W) variant

SEO Keywords: HLA-DRB1 Shared Epitope, PTPN22 R620W, PhytoIntelligence, Citrullination, ACPA, Immunomodulation, Precision Phytotherapy, T-Cell Signaling, JAK-STAT inhibition.

2. PATHOPHYSIOLOGY: SIGNALING NETWORKS & ESCAPE PATHWAYS

2.1 The Genomic Collision: HLA-DRB1 & PTPN22

The etiology of RA in the target phenotype is driven by a synergistic failure of central tolerance and peripheral regulation. The *HLA-DRB1* Shared Epitope (SE) encodes

a distinct amino acid motif ($^{70}QKRAA^{74}$, $^{70}QRRRAA^{74}$, or $^{70}RRRAA^{74}$) in the third hypervariable region of the DR β 1 chain. This electrostatic signature facilitates the high-affinity binding of citrullinated peptides (generated by PAD4) to the MHC Class II cleft.

Concurrently, the *PTPN22* C1858T polymorphism results in an arginine-to-tryptophan substitution (R620W) in the Lyp phosphatase. While R620W exhibits gain-of-function phosphatase activity, it paradoxically acts as a loss-of-function in negative regulation due to the disruption of the Lyp-Csk complex. This leads to a lowered threshold for T-cell Receptor (TCR) activation and the escape of autoreactive T-cell clones.

2.2 Signal Transduction Cascade

The pathological cascade operates via the following vector $\vec{V}_{path}$:

$$\vec{V}_{path} = \int_{t_0}^{t_{final}} (S_{TCR} \cdot \alpha_{SE} + S_{Cyt} \cdot \beta_{JAK}) dt \quad (1)$$

Where S_{TCR} represents hyperactive TCR signaling (ZAP-70/LAT phosphorylation), α_{SE} is the SE-mediated antigen presentation coefficient, and S_{Cyt} represents the IL-6/TNF- α feedback loop mediated by JAK/STAT.

2.3 Escape Pathways

Conventional DMARDs often fail due to:

1. **MAPK Divergence:** Blockade of JAK/STAT leads to compensatory upregulation of p38 MAPK and NF- κ B pathways.
2. **Apoptosis Resistance:** Synovial fibroblasts (FLS) acquire a semi-transformed phenotype (Bcl-2 upregulation) resistant to standard apoptotic signals.

3. B-CES FORMULATION: MODULE A (THE BENCH)

The Bio-Chemo-Electric Synergy (B-CES) formulation is engineered to simultaneously disrupt the MHC-Peptide-TCR trimolecular complex and restore Lyp-Csk functional equilibrium.

3.1 Ligand Matrix

Ligand	Dosage	Mechanism of Action
Curcumin (95%)	20 μ M	JAK1/JAK3 inhibition; Suppression of PAD4 expression.
EGCG	15 μ M	Direct binding to HLA-DRB1 cleft; competitive inhibition of cit-peptide.
Triptolide	20 nM	Inhibition of XPB subunit of TFIIH; induces apoptosis in RA-FLS.
Boswellic Acid	10 μ M	Non-redox 5-LOX inhibition; reduces leukotriene biosynthesis.
Quercetin	25 μ M	Zinc ionophore; modulates PTPN22 phosphatase activity.

Table 1: B-CES Ligand Dosages for *In Vitro* Application

3.2 Synergistic Calculation

The Combination Index (CI) must satisfy $CI < 1$ for synergy according to the Chou-Talalay method:

$$CI = \frac{(D)_1}{(D_x)_1} + \frac{(D)_2}{(D_x)_2} \quad (2)$$

The formulated ratio aims for a $CI \approx 0.65$, optimizing apoptotic induction in autoreactive T-cells while preserving viability in healthy PBMC controls.

4. LABORATORY SOP: VALIDATION PROTOCOLS

4.1 Cell Line Genotyping

- **Target Line A:** Jurkat T-cells transfected with *PTPN22* R620W construct.
- **Target Line B:** HEK293T cells expressing *HLA-DRB1*04:01* and *HLA-DRA*.
- **Control Line:** Jurkat T-cells (Wild Type *PTPN22*).

4.2 Experimental Design ($n = 6$ replicates)

Assay 1: Citrullinated Peptide Binding Competition

1. Incubate HLA-DRB1*04:01 cells with biotinylated cit-fibrinogen peptides.
2. Treat with EGCG gradient (0, 5, 10, 15, 20 μ M).
3. Measure bound peptide via Flow Cytometry (Streptavidin-PE).

Assay 2: TCR Signaling Phospho-Flow

1. Stimulate PTPN22 R620W Jurkat cells with anti-CD3/CD28.
2. Apply B-CES Formulation.
3. Lyse and Immunoblot for p-Lck (Y394), p-ZAP70 (Y319), and p-LAT.

Assay 3: Cytokine Secretion Profile ELISA quantification of supernatant IL-17A, IL-6, and TNF- α post-treatment (24h/48h).

5. LIMITATIONS & FALSIFICATION MATRIX

5.1 The Null Hypothesis (H_0)

H_0 : The administration of the B-CES formulation yields no statistically significant difference ($p > 0.05$) in the displacement of citrullinated peptides from HLA-DRB1*04:01 or the reduction of p-ZAP70 levels in PTPN22 R620W mutants compared to vehicle control (DMSO 0.1%).

5.2 Falsification Constraints

- **Bioavailability:** *In vitro* concentrations (μM) may not translate to serum concentrations in *in vivo* models without liposomal or nanoparticle delivery systems.
- **Off-Target Toxicity:** If cell viability (MTT assay) drops below 80% in control PBMCs, the protocol is invalid.
- **Genetic Heterogeneity:** The protocol specifically targets SE+ and R620W+ genotypes; efficacy may be negligible in seronegative RA.

6. UDOR 2025 SCORING: ETHICAL ALIGNMENT

This research protocol is evaluated against the *Universal Declaration of Rights (UDOR) 2025* framework for ethical bio-sovereignty.

- **Article 1 (Right to Existence):** Compliant. The protocol seeks to restore homeostasis without genetic ablation.
- **Article 2 (Sovereign Bodily Autonomy):** Compliant. Data is open-source; application is voluntary.
- **Article 3 (Freedom from Coercion):** Compliant. Non-pharmaceutical dependencies.
- **Article 4 (Right to Knowledge):** Compliant. Full transparency of mechanisms and limitations.
- **Article 5 (Protection of Future Generations):** Compliant. Epigenetic modulation potential without germline editing.

UDOR Score: 5/5 (Fully Aligned).

7. BIBLIOGRAPHY

- [1] Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. *Arthritis Rheum.* 1987;30(11):1205-1213.
- [2] Begovich AB, Carlton VE, Honigberg LA, et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. *Am J Hum Genet.* 2004;75(2):330-337.
- [3] Bottini N, Musumeci L, Alonso A, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. *Nat Genet.* 2004;36(4):337-338.
- [4] Vang T, Congia M, Macis MD, et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. *Nat Genet.* 2005;37(12):1317-1319.
- [5] Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Rheumatol.* 2016;68(1):1-26.
- [6] Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. *Int J Biochem Cell Biol.* 2009;41(1):40-59.
- [7] Ahmed S, Marotte H, Kwan K, et al. Epigallocatechin-3-gallate inhibits interleukin-6-induced signaling and production of C-reactive protein in human hepatocytes. *Arthritis Rheum.* 2008;58:212-221.
- [8] Li XJ, Jiang ZZ, Zhang LY. Triptolide: progress on research in pharmacodynamics and toxicology. *J Ethnopharmacol.* 2014;155(1):67-79.
- [9] Ammon HP. Boswellic acids in chronic inflammatory diseases. *Planta Med.* 2006;72(12):1100-1116.
- [10] Scally SW, Petersen J, Law SC, et al. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. *J Exp Med.* 2013;210(12):2569-2582.
- [11] Firestein GS. Evolving concepts of rheumatoid arthritis. *Nature.* 2003;423(6937):356-361.
- [12] McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. *N Engl J Med.* 2011;365(23):2205-2219.
- [13] Klareskog L, Rönnelid J, Lundberg K, Padyukov L, Alfredsson L. Immunity to citrullinated proteins in rheumatoid arthritis. *Annu Rev Immunol.* 2008;26:651-675.
- [14] Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. *Cancer Res.* 2010;70(2):440-446.
- [15] Vila LM. Phytochemicals in the treatment of Rheumatoid Arthritis and Systemic Lupus Erythematosus. *J Clin Med.* 2020;9(1):234.
- [16] Stanford SM, Bottini N. PTPN22: the archetypal non-HLA autoimmune gene. *Nat Rev Rheumatol.* 2014;10(10):602-611.
- [17] Zhang Y, Wang S, Li Y, et al. Sophisticated roles of PTPN22 in autoimmunity. *Front Immunol.* 2015;6:294.
- [18] Schett G, Elewaut D, McInnes IB, Dayer JM, Gonzalez-Gay MA. How cytokine networks fuel inflammation: Toward a cytokine-based disease taxonomy. *Nat Med.* 2013;19(7):822-824.
- [19] Landry MSS. PhytoIntelligence: The Sovereign Approach to Autoimmunity. *Priv Circ.* 2024.

- [20] The Universal Declaration of Rights (UDOR).
Sovereign International Consortium. 2025.